Circulating Biomarkers in Pancreatic Cancer Patients Treated With FOLFIRINOX
To treat or not to treat?

1. To treat or not to treat, that remains the question. (This thesis)
2. Circulating TP53 mutations in patients with pancreatic cancer could predict response to FOLFIRINOX. (This thesis)
3. Expression of miR-373-3p and miR-194-5p in patients with pancreatic cancer are predictive markers for early tumor progression during FOLFIRINOX. (This thesis)
4. Low circulating cytokine IL-1RA levels after one cycle of FOLFIRINOX in patients with pancreatic cancer are associated with early tumor progression during FOLFIRINOX. (This thesis)
5. Fear of clinical deterioration due to FOLFIRINOX should not be a reason to refrain from treatment. (This thesis)
6. Immunological combination treatment holds the key to improving survival in pancreatic cancer. (Sodergren et al., Journal of Cancer Research and Clinical Oncology, 2020)
7. If it were not for the great variability among individuals medicine might as well be a science and not an art. (Sir William Osler)
8. Surgeons can cut out everything except cause. (Herbert M. Shelton)
9. If we knew what it was we were doing, it would not be called research. (Albert Einstein)
10. Declare the past, diagnose the present, foretell the future. (Hippocrates)
11. Genius is one percent inspiration and ninety-nine percent perspiration. (Thomas A. Edison)

Fleur van der Sijde, 8 december 2021